Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study

被引：0
|
作者：
Chen, K. [1 ]
Fan, Y. [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Oncol, Canc Hosp, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21P
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [41] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Adjuvant osimertinib in patients with completely resected, stage IB-IIIB non-small cell lung cancer with uncommon EGFR mutations: A phase II, open-label, single arm, multicenter, exploratory study
    Liu, C.
    Mei, J.
    Lin, F.
    Lin, Y.
    Chen, Y.
    Liu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S113 - S114
  • [43] Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)
    D'Arcangelo, M.
    Tassinari, D.
    De Marinis, F.
    Delmonte, A.
    Galetta, D.
    Cecere, F.
    Pilotto, S.
    Zanelli, F.
    Bonanno, L.
    Landi, L.
    D'Inca, F.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S644 - S644
  • [44] DETECTING EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Hammoudeh, Z. A.
    Antonova, O.
    Staneva, R.
    Nikolova, D.
    Kyuchukov, Y.
    Penev, A.
    Mintchev, T.
    Koleva, V
    Hadjidekova, S.
    Toncheva, D.
    BALKAN JOURNAL OF MEDICAL GENETICS, 2018, 21 (01) : 13 - 17
  • [45] Predicting survival in metastatic non-small cell lung cancer patients with poor ECOG-PS: A single-arm prospective study
    Cunha, Mateus Trinconi
    de Souza Borges, Ana Paula
    Jardim, Vinicius Carvalho
    Fujita, Andre
    de Castro Jr, Gilberto
    CANCER MEDICINE, 2023, 12 (04): : 5099 - 5109
  • [46] Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial
    Liu, Z.
    Liu, M.
    Xu, J.
    Fu, H.
    Zhu, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S1038 - S1038
  • [47] The clinical efficacy and safety of sintilimab plus anlotinib for unresectable intrahepatic cholangiocarcinoma (ICC): A prospective, single-arm phase II study.
    Cheng, Jian-Wen
    Yang, Xin-Rong
    Xu, Yang
    Huang, Xiao-Wu
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
    Ozawa, Yuichi
    Sugimoto, Takeya
    Azuma, Yuichiro
    Harutani, Yuhei
    Yoshikawa, Takanori
    Yamamoto, Nobuyuki
    Kanai, Kuninobu
    BMJ OPEN, 2020, 10 (07):
  • [49] Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): A single-arm, prospective phase II study
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1040 - S1040
  • [50] Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
    Zhang, Tianli
    Wan, Bing
    Zhao, Yuan
    Li, Chuling
    Liu, Hongbing
    Lv, Tangfeng
    Zhan, Ping
    Song, Yong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 302 - 316
12345